Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8TCE9
UPID:
PPL13_HUMAN
Alternative names:
Charcot-Leyden crystal protein 2; Galectin-14
Alternative UPACC:
Q8TCE9; A8MPV8; B2R530; C5HZ19; Q7Z4X8; Q96KD4; Q96KD5; Q96KD6; Q9NR03
Background:
Placental protein 13-like, also known as Charcot-Leyden crystal protein 2 or Galectin-14, is a protein that plays a crucial role in cellular processes. It is known for its ability to bind beta-galactoside and lactose, showcasing a significant function in carbohydrate recognition. This protein is a strong inducer of T-cell apoptosis, highlighting its potential impact on immune regulation.
Therapeutic significance:
Understanding the role of Placental protein 13-like could open doors to potential therapeutic strategies. Its unique ability to induce T-cell apoptosis makes it a promising target for the development of treatments aimed at modulating immune responses.